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Background: Cerebral malaria is a rapidly developing encephalopathy caused by the apicomplexan parasite
Plasmodium falciparum. Drugs currently in use are associated with poor outcome in an increasing number of cases
and new drugs are urgently needed. The potential of the medicinal plant Azadirachta indica (Neem) for the
treatment of experimental cerebral malaria was evaluated in mice.
Methods: Experimental cerebral malaria was induced in mice by infection with Plasmodium berghei ANKA. Infected
mice were administered with Azadirachta indica ethanolic extract at doses of 300, 500, or 1000 mg/kg
intraperitoneally (i.p.) in experimental groups, or with the anti-malarial drugs chloroquine (12 mg/kg, i.p.) or
artemether (1.6 mg/kg, i.p.), in the positive control groups. Treatment was initiated at the onset of signs of brain
involvement and pursued for five days on a daily basis. Mice brains were dissected out and processed for the study
of the effects of the extract on pyramidal cells’ fate and on markers of neuroinflammation and apoptosis, in the
medial temporal lobe.
Results: Azadirachta indica ethanolic extract mitigated neuroinflammation, decreased the severity of brain oedema,
and protected pyramidal neurons from apoptosis, particularly at the highest dose used, comparable to chloroquine
and artemether.
Conclusions: The present findings suggest that Azadirachta indica ethanolic extract has protective effects on
neuronal populations in the inflamed central nervous system, and justify at least in part its use in African and
Asian folk medicine and practices.
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Cerebral malaria is a rapidly developing encephalopathy
that represents the most severe neurological compli-
cation of infection with Plasmodium falciparum. Cere-
bral malaria mainly occurs in resource-poor tropical
countries, and mostly affects children [1,2]. Surviving
patients display neurologic and cognitive deficits, in-
cluding consciousness impairment, cerebellar ataxia,
seizures, and coma, making cerebral malaria a major
cause of childhood neurodisability in endemic areas* Correspondence: farahnamohammed@hotmail.com
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reproduction in any medium, provided the or[3-6]. The pathogenesis of neuro-cognitive sequelae is
poorly understood.
Experimental models of cerebral malaria have been
providing new mechanistic insights that will help de-
velop efficient neuro-protective interventions. The non-
human pathogenic parasite Plasmodium berghei has
been used to induce experimental cerebral malaria in
mice that has some features comparable to the human
disease [7-9]. Experimental evidence suggests that the
vast array of pro-inflammatory molecules released by the
host to fight the infection and alterations due to parasite
sequestration in the microvessels cause leakage of
plasma into the parenchyma resulting in brain oedema,
and may contribute to the subsequent blood–braind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by danger or pathogen-associated molecules would trigger
a sustained detrimental neuroinflammatory response lead-
ing to the recruitment of circulating immune cells. The
latter cells would induce death through cell-mediated
apoptosis in sensible neuronal populations, by triggering
pathways such as caspase 3 and Fas-Fas ligand [12-14].
Previous studies and reports have shown that such
inflammation-triggered apoptosis can induce cerebellar
ataxia when affecting Purkinje cells in the cerebellum
[15-17]. Similarly, apoptosis affecting cortical neurons may
explain many other neurologic deficits observed in experi-
mental cerebral malaria, such as cognitive impairment or
seizures [18-21]. Overall, these findings corroborate the al-
terations reported in humans [9,14,22,23]. New effective
drugs are urgently needed for cerebral malaria treatment
due to the development of parasite chemoresistance, and
to improve current drugs’ poor treatment outcome [24-26].
Azadirachta indica is a plant commonly used in the
African and Asian folk medicine and practices [27-31].
Anti-malarial effects of A. indica extracts have been
demonstrated [32-36], as well as the neuro-protective ef-
fects on Purkinje cells of P. berghei-infected mice suc-
cessfully mitigating cerebellum malaria [16]. The present
study addresses the potential of A. indica extract for the
protection of cortical and sub-cortical pyramidal neu-
rons of P. berghei-infected mice, considering the implica-
tions for the treatment of cerebral malaria-associated
cortical deficits.Methods
Experimental procedure
Thirty five mice, divided into seven groups (five animals
per group), were used in this study. These groups were:
i) a disease control group made of untreated P. berghei-
infected mice; ii) two positive control groups made of
P. berghei-infected mice treated with the commercially
available anti-malarial drugs chloroquine (12 mg/kg in dis-
tilled water, i.p.) and artemether (1.6 mg/kg in olive oil,
i.p.); iii) three experimental groups made of P. berghei-
infected mice treated with A. indica ethanolic extract at
doses 300, 500, or 1000 mg/kg (i.p.); iv) and a group of un-
infected healthy animals. Parasitaemia, body weight, core
body temperature, and signs of brain involvement were
monitored. Treatment was started when the number of
parasitized red blood cells was >5% (severe malaria indica-
tor) and was associated with signs of brain involvement.
Treatment was pursued for five days on a daily basis. Mice
either died spontaneously or were sacrificed by ether
inhalation-induced deep anesthesia once signs of disease
terminal stage (hypothermia, ptosis, and convulsion) [37],
were observed. Uninfected mice were sacrificed concomi-
tantly with the last animals to check for disease terminalstage signs. For all animals, brains were dissected out and
processed for histopathological analysis.
Animals and infection
Male Swiss albino mice (weighing 26.5 ± 3.0 g, aged 6 ±
1 week) were donated by Sudan National Health Labora-
tory (Khartoum, Sudan). Mice were maintained at a 12:12
light/dark cycle and were given ad libitum access to food
(standard diet) and water. For infection, mice were admin-
istered (i.p.) with a load of 10 × 106 parasitized red blood
cells containing P. berghei ANKA. The parasitaemia was
checked by blood smear Giemsa-staining. All procedures
received approval from the Ethical Committee of the Insti-
tute of Endemic Diseases of the University of Khartoum
and animals were handled according to institutional
guidelines. Plasmodium berghei ANKA blood-stage cryo-
stabilates were kindly donated by Dr. C.R. Pillai (National
Institute of Malaria, New Delhi, India).
Preparation of the extract
Fresh leaves of A. indica were collected in Khartoum re-
gion, where they are commonly used in folk medicine to
treat malaria [33], and shade-dried. Dry leaves were
grinded, and 1500 g of powder were macerated in 15 L
of ethanol for three consecutive days at room tem-
perature. A 1 mg/mL stock solution was obtained by fil-
tration and boiling of the supernatant, and was stored at
4°C until use. Three doses of A. indica, i.e. 300, 500, and
1,000 mg/kg, were administered to the respective experi-
mental groups once a day for five days. These regimens
were chosen in accordance with previous pharmaco-
logical studies in malaria models [16,28].
Pyramidal neuron density and brain oedema
Brains dissected out were fixed in 10% neutral buffered
formaldehyde, then paraffin-embedded and cut sagittally
(section thickness: 5 μm). Sections were deparaffinized
in xylene, rehydrated, and processed for haematoxylin-
eosin (H&E) staining. The pyramidal neuron volumetric
density, i.e. the proportion of brain subfield that is occu-
pied by pyramidal neuronal cell bodies, was determined
as described by Highley and colleagues [38]. Pyramidal
neurons were counted on five consecutive sections, in
the medial temporal lobe, using a light microscope with
a fixed 1 cm grid eyepiece under 40× objective. Brain
oedema was assessed by giving a severity score integrat-
ing histopathological parameters, such as the importance
(how big) and frequency (how numerous) of fluid built
up in the brain parenchyma, on the H&E stained sec-
tions [39,40].
Immunohistochemistry
The sections processed for immunohistochemical labeling
were deparaffinized in xylene, rehydrated, and endogenous
Figure 1 Pyramidal cell density. Effect of Azadirachta indica on
the volumetric density of pyramidal neurons in Plasmodium
berghei-infected (inf.) mice. Note the increase in volumetric density
induced by treatment with chloroquine (chlor.), artemether (artem.),
and all doses of A. indica extract used. Data are mean ± SEM.
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pre-incubated in normal serum buffer solution (Diagnos-
tic BioSystems, Serpentine, CA, USA), and incubated for
3 h in either rabbit anti-caspase-3, anti-FAS, anti-FAS lig-
and, anti-tumor necrosis factor (TNF), or anti-nitric oxideFigure 2 Caspase 3 expression. A. Micrographs showing the expression
left): an uninfected mouse, an untreated Plasmodium berghei-infected mou
indica crude extract. B. Effect of A. indica on caspase 3 expression in pyram
following treatment with chloroquine (chlor.), artemether (artem.), and A. insynthase (NOS) primary antibody buffer solution (dilution
factor 1:40, Lica Biosystem Newcastle Ltd, UK), followed
by a biotinylated secondary antibody and streptavidin-
conjugated horseradish peroxidase (Vision Biosystems
Novocastra, Novocastra Laboratories Ltd., Newcastle,
UK) prepared according to the kit instructions. The sec-
tions were incubated with 3,3′-diaminobenzidine hydro-
chloride (DAB) chromogen substrate (Vision Biosystems
Novocastra) according to the manufacturer’s instructions,
and counterstained with H&E. P value < .05 was consid-
ered significant. Thorough washes between steps were
performed using immune wash buffer (Vision Biosystems
Novocastra). Sections were dehydrated through a graded
ethanol series, cleared in xylene, and covered with a thin
glass coverslip. The fraction of pyramidal neurons express-
ing each of the studied markers, i.e. the markers of apop-
tosis caspase 3, Fas, and Fas ligand, and the markers of
neuroinflammation-triggered apoptosis TNF and NOS, was
determined using a light microscope under 40× objective.Statistical analysis
Data obtained from infected treated or uninfected groups
were compared to those obtained from the infected un-
treated group using one-way ANOVA followed by LSDof caspase 3 in pyramidal neurons of representative examples of (from
se (inf.), and a P. berghei-infected mouse treated with Azadirachta
idal neurons of P. berghei-infected mice. Note the significant decrease
dica extract (dose 1,000 mg/kg). Data are mean ± SEM.
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tistically significant. All data were expressed as a percent-
age of the value obtained in the infected untreated group.
Data are presented as mean ± SEM (n = 5).
Results
General observations
The early signs of disease started five days after infection
in the majority of P. berghei-infected animals, i.e. in the
disease control group and in animals treated with
chloroquine, artemether, or one of the three doses of
A. indica extract. Cerebral malaria signs appeared at day
6 ± 1 post-infection. The most recurrent ones were a ruf-
fled fur, locomotor impairments, and sickness behavior
(anorexia, cachexia, fever) associated with body weight
loss. Animals treated with A. indica, chloroquine orFigure 3 Fas and Fas ligand expression. A. Micrographs showing the ex
(from left): an uninfected mouse, an untreated Plasmodium berghei-infecte
Azadirachta indica crude extract. B. Effect of A. indica on the expression of
infected mice. Note the significant decrease in expression of both molecul
and A. indica extract (more marked at dose 1,000 mg/kg). Data are mean ±artemether did not displayed fever (as evaluated by
increases in core body temperature), and from dose
500 mg/kg of extract locomotor disturbances and body
weight loss were improved. Parasitaemia was decreased
in infected mice following treatment with chloroquine or
arthemether (from 6.1 ± 1.8% to 1.2 ± 0.4%, P < 0.05), but
no significant change was observed in A. indica-treated
animals, as previously reported [16].
Azadirachta indica extract did not protected infected
mice from death, unlike chloroquine and artemether, al-
though the highest doses slightly (not significantly) de-
layed death time. Infected untreated mice spontaneously
died at day 9 ± 1 post-infection, A. indica-treated mice
treated with the highest doses started to die at day 11,
whereas no animal died in groups treated with chloro-
quine and artemether during the time of observation.pression of Fas in pyramidal neurons of representative examples of
d mouse (inf.), and a P. berghei-infected mouse treated with
Fas (upper) and Fas ligand (lower) in pyramidal neurons of P. berghei-
es following treatment with chloroquine (chlor.), artemether (artem.),
SEM.
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the extract were sacrificed two days after (day 13 post-
infection) as terminal signs of cerebral malaria, i.e.
hypothermia, ptosis, ataxia, and convulsion, were ob-
served. All other animals, including those treated with
chloroquine or artemether as well as uninfected ones
were also sacrificed then.
Extract effect on pyramidal neuron density
The effect of A. indica on P. berghei-infected mice pyram-
idal neuron volumetric density is shown in Figure 1. The
volumetric density of pyramidal neurons of mice treated
with A. indica extract was significantly higher at all doses,
in comparison to the infected untreated group (P < 0.01),
and was comparable (non-significantly different [41]) to
the values observed in the infected groups treated with
chloroquine or artemether, and to uninfected group values,
which were also significantly different from infected un-
treated group values (P < 0.01 for all three groups).
Extract effect on caspase 3 expression
The effect of A. indica on the expression of caspase 3 in
pyramidal neurons of P. berghei-infected mice is shown
in Figure 2. Pyramidal neurons of mice treated withFigure 4 TNF expression. A. Micrographs showing the expression of tum
examples of (from left): an uninfected mouse, an untreated Plasmodium be
with Azadirachta indica crude extract. B. Effect of A. indica on the expressio
significant decrease in expression following treatment with chloroquine (chA. indica extract displayed a significant decrease in
caspase 3 expression at the highest dose, in comparison
to the infected untreated group (P < 0.05), comparable
to the decreases induced by chloroquine (P < 0.05 vs.
infected untreated group) or artemether (P < 0.05 vs.
infected untreated group).
Extract effect on Fas and Fas ligand expression
The effect of A. indica on Fas and Fas ligand expression
in P. berghei-infected mice pyramidal neurons is shown
in Figure 3. Pyramidal neurons of mice treated with
A. indica extract displayed a significant decrease in Fas
expression at the highest dose, in comparison to the
infected untreated group (P < 0.05) and a decrease in Fas
ligand expression at doses 500 and 1000 mg/kg (P < 0.05
vs. infected untreated group). The significant decreases
observed were comparable to those induced by chloro-
quine (P < 0.05 for Fas and P < 0.01 for Fas ligand vs.
infected untreated group) or artemether (P < 0.05 for Fas
and P < 0.01 for Fas ligand vs. infected untreated group).
Extract effect on TNF expression
The effect of A. indica on TNF expression in pyramidal
neurons of P. berghei-infected mice is shown in Figure 4.or necrosis factor (TNF) in pyramidal neurons of representative
rghei-infected mouse (inf.), and a P. berghei-infected mouse treated
n of TNF in pyramidal neurons of P. berghei-infected mice. Note the
lor.), artemether (artem.), or any of the doses of A. indica extract used.
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displayed a significant decrease in TNF expression at all
doses used, in comparison to the infected untreated
group (P < 0.01 at 1000 mg/kg). This effect was compar-
able to the decrease in TNF expression induced by
chloroquine (P < 0.01 vs. infected untreated group) or
artemether (P < 0.05 vs. infected untreated group).
Extract effect on NOS expression
The effect of A. indica on the expression of NOS in
P. berghei-infected mice pyramidal neuron is shown in
Figure 5. Azadirachta indica extract induced a signifi-
cant decrease in NOS expression, in comparison to the
infected untreated group. However, such decrease was
statistically significant and comparable to the effect of
chloroquine (P < 0.05 vs. infected untreated group) or
artemether (P < 0.05 vs. infected untreated group) only
at the highest dose used (1000 mg/kg, P < 0.05).
Extract effect on brain oedema severity
The effect of A. indica extract on brain oedema severity in
P. berghei-infected mice is shown in Figure 6. Azadirachta
indica extract induced a significant decrease in brain
oedema severity at all doses used, in comparison to the
infected untreated group (P < 0.05), which was comparableFigure 5 NOS expression. A. Micrographs showing the expression of nitr
examples of (from left): an uninfected mouse, an untreated Plasmodium be
with Azadirachta indica crude extract. B. Effect of A. indica on the expressio
significant decrease in expression following treatment with chloroquine, arto the effect of chloroquine (P < 0.01 vs. infected un-
treated group) or artemether (P < 0.05 vs. infected un-
treated group).Discussion
The present study points out the protective effects of
A. indica extract on pyramidal neurons in experimen-
tal cerebral malaria induced by P. berghei-infection in
mice.Protective effects on pyramidal neurons
Pyramidal neuron density study revealed comparable
values between P. berghei-infected mice treated with the
extract of A. indica and uninfected mice, which were
significantly different from untreated P. berghei-infected
mice (disease control group) where a significant decrease
in pyramidal neuron density, characteristic of cerebral
malaria insult [14,18-20], was observed. These findings
suggest that the extract protected pyramidal neurons
from cerebral malaria-induced apoptosis. In order to fur-
ther characterize these effects, the expression of apop-
tosis markers was studied, considering the importance of
this phenomenon in cerebral malaria-associated enceph-
alopathy [7-9].ic oxide synthase (NOS) in pyramidal neurons of representative
rghei-infected mouse (inf.), and a P. berghei-infected mouse treated
n of NOS in pyramidal neurons of P. berghei-infected mice. Note the
temether, and A. indica extract highest dose. Data are mean ± SEM.
Figure 6 Brain oedema. A. Micrograph showing a representative case of highest brain oedema severity score. B. Effect of Azadirachta indica on
the severity of brain oedema in Plasmodium berghei-infected (inf.) mice. Note the significant decrease in brain oedema severity following
treatment with chloroquine (chlor.), artemether (artem.), or any of the doses of A. indica extract used. Data are mean ± SEM.
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The markers of apoptosis studied were caspase 3, Fas,
and Fas ligand, which are commonly used for the de-
tection of apoptosis in neuronal populations [13,19].
Azadirachta indica extract induced a striking decrease
in caspase 3, Fas, and Fas ligand expressions on pyram-
idal neurons of P. berghei-infected mice, particularly at
the highest dose used. Considering that these markers
are associated with the risk for neuron apoptosis [13,19],
the present finding indicates that A. indica extract has
anti-apoptotic effects on pyramidal neurons in experimen-
tal cerebral malaria. The latter effects probably account for
at least part of the protective effects of the extract against
pyramidal neuron death in treated P. berghei-infected mice.Considering that the pro-inflammatory environment, and
particularly infiltrating immune cells, contribute to the
detrimental effects of cerebral malaria on neurons, includ-
ing apoptosis in sensible neuronal populations [12,14,42],
through extrinsic mediators of apoptosis such as TNF and
NOS [12,43,44], we have addressed the effect of A. indica
extract on these inflammatory triggers of apoptosis in
P. berghei-infected mice.
Mitigation of neuroinflammatory triggers of apoptosis
and brain oedema severity
Treatment with A. indica extract induced decreases in pyr-
amidal neuron expression of TNF and NOS in P. berghei-
infected mice as compared with disease control group,
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brain parenchyma. Besides, considering that brain oedema
is a major causative of the inflammatory response in
the brain parenchyma (through infiltrating danger or
pathogen-associated molecules [10,11]), the decrease in
oedema severity observed in groups treated with the ex-
tract in the present study, indicate that the aforementioned
anti-inflammatory effects may be mediated, at least in part,
by protective effects on brain vessels. These findings are in
agreement with our precedent observations in Purkinje
cells of P. berghei-infected mice, where A. indica also
displayed neuroprotective effects [16]. Comparable effects
of A. indica extract have been reported in other models of
detrimental neuroinflammation associated with brain
oedema, including cerebral post-ischemic reperfusion and
hypoperfusion in rats [45,46]. Thus, the findings herein
reported confirm that A. indica extract has neuro-
protective effects in experimental cerebral malaria, and
indicate that such effect may be mediated through protect-
ive effects on brain vessels and the consequent decrease in
neuroinflammation severity. Not surprisingly and interest-
ingly, chloroquine and artemether, drugs in use for cere-
bral malaria treatment in the field [37,47], also induced
similar effects, corroborating their beneficial effects re-
ported in humans, and pointing out at least part of the
mechanisms accounting for these effects. It appears, there-
fore, that future studies aiming at unraveling the active
principle(s) accounting for the beneficial effects of
A. indica extract reported may provide key elements for
the development of new drugs for cerebral malaria.
Subjecting the bioactive agents of Azadirachta indica which
have already been characterized, such as gedunin [33, 48],
to a similar study may provide better insights into the
neuroprotective effects herein described.
Conclusions
Azadirachta indica extract did not protected infected mice
from death from cerebral malaria, although the highest
doses slightly delayed death time. However, A. indica ex-
tract displayed neuroprotective effects mediated probably
by mitigating oedema build up, and modulating both
neuroinflammatory triggers of apoptosis and apoptosis sig-
naling pathways. The use of extracts of A. indica in African
and Asian folk medicine and practices for the treatment of
malaria and cerebral malaria is justified. Characterization
of the active principle(s) accounting for these effects will
probably provide new drugs, which are particularly needed
in the current context of increased chemoresistance to
chloroquine.
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